Clinical Trials Browser

Phase 2 × Renal Insufficiency × Bortezomib × Clear all

Multiple Myeloma, Renal Insufficiency

NCT04352205 2024-07-01

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Phase 2 Terminated

17 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Phase 2 Unknown

51 enrolled

Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02424851 2022-01-27

OPTIMAL

Phase 2 Completed

31 enrolled 13 charts

Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01084837 2015-09-17

RENVEL

Phase 2 Completed

60 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT00401804 2013-01-24

Bortezomib-Dexamethasone-Doxorubicin-Study

Phase 2 Completed

72 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

Clinical Trials

VICD

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

OPTIMAL

RENVEL

Bortezomib-Dexamethasone-Doxorubicin-Study